Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Envista Holdings CorpNVST · Entity 4007 | Senior Vice President | April 04, 2023 | April 06, 2023 |
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | EVP & Chief Operating Officer | August 15, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Envista Holdings Corp
Report date April 04, 2023 · Filed April 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Envista deferred contribution programs - Envista Stock FundSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,431 |
Reported balance
After 2023-04-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-04-04 · Grant · Acquired 516 · Balance 1,431 F1: The notional shares convert on a one-for-one basis. F2: Company contributions to the Excess Contribution Program ("ECP") consist of matching contributions (based on amounts the reporting person voluntary defers into the Envista Deferred Compensation Plan) and/or non-elective contributions. A participant vests in the matching contribution in the ECP made each year on the first anniversary after it is credited to the participant's account. A participant vests in the non-elective contribution in the ECP made each year on the later of the first anniversary after it is credited to the participant's account, or the date the participant has completed three years of service with Envista. F3: Represents the Company's annual contribution to the Envista stock fund (the "ECP Stock Fund") in the reporting person's ECP account. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Envista common stock, calculated by dividing the contribution amount by the closing price of Envista common stock as reported on the NYSE as of the last day in January of the year in which the contribution is made. The price shown in Table II, Column 8 is the closing price per share of Envista common stock as reported on the NYSE on the date the contribution was actually made (or the closing price for the immediately preceding business day, if such date is not a business day). F4: Consists of unfunded, notional shares of Envista common stock in the Envista stock fund of the reporting person's ECP account. |
Filing footnotes · ownership attribution and instrument terms
F1: The notional shares convert on a one-for-one basis.
F2: Company contributions to the Excess Contribution Program ("ECP") consist of matching contributions (based on amounts the reporting person voluntary defers into the Envista Deferred Compensation Plan) and/or non-elective contributions. A participant vests in the matching contribution in the ECP made each year on the first anniversary after it is credited to the participant's account. A participant vests in the non-elective contribution in the ECP made each year on the later of the first anniversary after it is credited to the participant's account, or the date the participant has completed three years of service with Envista.
F3: Represents the Company's annual contribution to the Envista stock fund (the "ECP Stock Fund") in the reporting person's ECP account. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Envista common stock, calculated by dividing the contribution amount by the closing price of Envista common stock as reported on the NYSE as of the last day in January of the year in which the contribution is made. The price shown in Table II, Column 8 is the closing price per share of Envista common stock as reported on the NYSE on the date the contribution was actually made (or the closing price for the immediately preceding business day, if such date is not a business day).
F4: Consists of unfunded, notional shares of Envista common stock in the Envista stock fund of the reporting person's ECP account.
TANDEM DIABETES CARE INC
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,290 |
Ending reported balance
After 2026-08-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-15 · Exercise / conversion · Acquired 1,010 · Balance 30,825 Row 2 · 2026-08-15 · Tax withholding · Disposed 535 · Balance 30,290 F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 7,067 |
Reported balance
After 2026-08-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-15 · Exercise / conversion · Disposed 1,010 · Balance 7,067 F2: Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.
F2: Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
F3: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
F4: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2026 Filed Aug 18, 2026 20:27 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 1,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000129 · wk-form4_1787084870.xml · derivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,067 Underlying: Common Stock · 1,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. F4 · derivative.expiration_date: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:27 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 535 | $22.72 | $12,155.20 |
DisclosureSEC source: 0001438133-26-000129 · wk-form4_1787084870.xml · nonDerivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,290 F1 · kind: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:27 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 1,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000129 · wk-form4_1787084870.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 3,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000116 · wk-form4_1784318840.xml · derivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,545 Underlying: Common Stock · 3,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: One-third of the RSUs granted on July 14, 2024 vested on July 14, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. F4 · derivative.expiration_date: One-third of the RSUs granted on July 14, 2024 vested on July 14, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 1,926 | $15.28 | $29,429.28 |
DisclosureSEC source: 0001438133-26-000116 · wk-form4_1784318840.xml · nonDerivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,815 F1 · kind: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 3,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000116 · wk-form4_1784318840.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:21 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 29,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000110 · wk-form4_1780431658.xml · derivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,136 Underlying: Common Stock · 29,136 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of the Issuer's common stock or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F2 · derivative.exercise_date: One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight (8) equal quarterly installments on the 15th of the month thereafter subject to the terms of the 2023 Plan. F2 · derivative.expiration_date: One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight (8) equal quarterly installments on the 15th of the month thereafter subject to the terms of the 2023 Plan. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:10 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 4,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000062 · wk-form4_1779221403.xml · derivative · entry 4 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,077 Underlying: Common Stock · 4,038 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:10 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantCommon Stock | 434 | $10.90 | $4,730.60 |
DisclosureSEC source: 0001438133-26-000062 · wk-form4_1779221403.xml · nonDerivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,105 F2 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2025, through May 15, 2026. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:10 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 2,139 | $12.82 | $27,421.98 |
DisclosureSEC source: 0001438133-26-000062 · wk-form4_1779221403.xml · nonDerivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,671 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:10 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 4,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000062 · wk-form4_1779221403.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:10 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 3,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000040 · wk-form4_1776456641.xml · derivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,181 Underlying: Common Stock · 3,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:10 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 1,926 | $20.66 | $39,791.16 |
DisclosureSEC source: 0001438133-26-000040 · wk-form4_1776456641.xml · nonDerivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,772 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:10 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 3,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000040 · wk-form4_1776456641.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 21:09 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 3,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000003 · wk-form4_1768943392.xml · derivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,817 Underlying: Common Stock · 3,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 21:09 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 2,118 | $21.07 | $44,626.26 |
DisclosureSEC source: 0001438133-26-000003 · wk-form4_1768943392.xml · nonDerivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,062 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 21:09 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 3,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000003 · wk-form4_1768943392.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantCommon Stock | 160 | $15.59 | $2,494.40 |
DisclosureSEC source: 0001438133-25-000209 · wk-form4_1763586392.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,544 F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of May 16, 2025, through November 17, 2025. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 20:21 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 3,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000177 · wk-form4_1760732477.xml · derivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,453 Underlying: Common Stock · 3,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 20:21 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 1,301 | $14.75 | $19,189.75 |
DisclosureSEC source: 0001438133-25-000177 · wk-form4_1760732477.xml · nonDerivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,384 F1 · shares: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 20:21 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 3,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000177 · wk-form4_1760732477.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:11 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 14,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000148 · wk-form4_1752783092.xml · derivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,089 Underlying: Common Stock · 14,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:11 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 5,205 | $15.20 | $79,116.00 |
DisclosureSEC source: 0001438133-25-000148 · wk-form4_1752783092.xml · nonDerivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,049 F1 · shares: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:11 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 14,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000148 · wk-form4_1752783092.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2025 Filed Jun 5, 2025 21:25 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 12,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000133 · wk-form4_1749158515.xml · derivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,115 Underlying: Common Stock · 12,115 shares Expires not disclosed F1 · security: Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 30, 2025 Filed Jun 5, 2025 21:25 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantPerformance Stock Unit · Derivative | 12,114 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000133 · wk-form4_1749158515.xml · derivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,114 Underlying: Common Stock · 12,114 shares Expires not disclosed F1 · security: Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F2 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the Company) common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2027 (the Measurement Date). The number of shares issued may range from 0% to 200% of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F2 · derivative.exercise_date: Each performance stock unit (PSU) represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the Company) common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2027 (the Measurement Date). The number of shares issued may range from 0% to 200% of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F2 · derivative.expiration_date: Each performance stock unit (PSU) represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the Company) common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2027 (the Measurement Date). The number of shares issued may range from 0% to 200% of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:05 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantCommon Stock | 171 | $19.30 | $3,300.30 |
DisclosureSEC source: 0001438133-25-000084 · wk-form4_1747692340.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,709 F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | PurchaseCommon Stock | 10,538 | $18.12 | $190,966.47 |
DisclosureSEC source: 0001438133-25-000042 · wk-form4_1741730755.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,538 F1 · price: This transaction was executed in multiple trades at prices ranging from $18.115 to $18.13 per share. The reported price reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:16 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 43,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000170 · wk-form4_1721247403.xml · derivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,634 Underlying: Common Stock · 43,634 shares Expires not disclosed F1 · security: Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). F1 · derivative.exercise_price: Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). F2 · derivative.exercise_date: Restricted stock units (RSU) vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F2 · derivative.expiration_date: Restricted stock units (RSU) vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:35 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantEnvista deferred contribution programs - Envista Stock Fund · Derivative | 516 | $38.73 Strike: $0.00 | $19,984.68 |
DisclosureSEC source: 0001757073-23-000031 · wf-form4_168081331017309.xml · derivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,431 Underlying: Common Stock · 516 shares Expires not disclosed F1 · derivative.exercise_price: The notional shares convert on a one-for-one basis. F2 · derivative.exercise_date: Company contributions to the Excess Contribution Program ("ECP") consist of matching contributions (based on amounts the reporting person voluntary defers into the Envista Deferred Compensation Plan) and/or non-elective contributions. A participant vests in the matching contribution in the ECP made each year on the first anniversary after it is credited to the participant's account. A participant vests in the non-elective contribution in the ECP made each year on the later of the first anniversary after it is credited to the participant's account, or the date the participant has completed three years of service with Envista. F2 · derivative.expiration_date: Company contributions to the Excess Contribution Program ("ECP") consist of matching contributions (based on amounts the reporting person voluntary defers into the Envista Deferred Compensation Plan) and/or non-elective contributions. A participant vests in the matching contribution in the ECP made each year on the first anniversary after it is credited to the participant's account. A participant vests in the non-elective contribution in the ECP made each year on the later of the first anniversary after it is credited to the participant's account, or the date the participant has completed three years of service with Envista. F3 · derivative.underlying_shares: Represents the Company's annual contribution to the Envista stock fund (the "ECP Stock Fund") in the reporting person's ECP account. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Envista common stock, calculated by dividing the contribution amount by the closing price of Envista common stock as reported on the NYSE as of the last day in January of the year in which the contribution is made. The price shown in Table II, Column 8 is the closing price per share of Envista common stock as reported on the NYSE on the date the contribution was actually made (or the closing price for the immediately preceding business day, if such date is not a business day). F3 · balance_after: Represents the Company's annual contribution to the Envista stock fund (the "ECP Stock Fund") in the reporting person's ECP account. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Envista common stock, calculated by dividing the contribution amount by the closing price of Envista common stock as reported on the NYSE as of the last day in January of the year in which the contribution is made. The price shown in Table II, Column 8 is the closing price per share of Envista common stock as reported on the NYSE on the date the contribution was actually made (or the closing price for the immediately preceding business day, if such date is not a business day). F4 · balance_after: Consists of unfunded, notional shares of Envista common stock in the Envista stock fund of the reporting person's ECP account. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 21:51 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantPerformance Share Unit · Derivative | 10,095 | $0.00 | $0.00 |
DisclosureSEC source: 0001757073-23-000013 · wf-form4_167762105466000.xml · derivative · entry 4 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,095 Underlying: Common Stock · 10,095 shares Expires not disclosed F4 · derivative.exercise_price: Consists of Performance Share Units ("PSUs") that will vest, if at all, based on certification of achievement of identified performance measures over a three-year performance period. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-200% of the amount reported depending on the level of performance achieved. F4 · derivative.exercise_date: Consists of Performance Share Units ("PSUs") that will vest, if at all, based on certification of achievement of identified performance measures over a three-year performance period. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-200% of the amount reported depending on the level of performance achieved. F4 · derivative.expiration_date: Consists of Performance Share Units ("PSUs") that will vest, if at all, based on certification of achievement of identified performance measures over a three-year performance period. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-200% of the amount reported depending on the level of performance achieved. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 21:51 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantEmployee Stock Option (Right to Buy) · Derivative | 13,340 | $0.00 Strike: $38.25 | $0.00 |
DisclosureSEC source: 0001757073-23-000013 · wf-form4_167762105466000.xml · derivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,340 Underlying: Common Stock · 13,340 shares Expires 2033-02-25 F3 · derivative.exercise_date: This Option will vest ratably on each anniversary of the date of grant over three years, subject to continued service through each such date. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 21:51 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantCommon Stock | 5,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001757073-23-000013 · wf-form4_167762105466000.xml · nonDerivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,838 F2 · shares: Consists of RSUs that will vest ratably on each anniversary of the date of grant over three years, subject to continued service through each such date. Each RSU will convert on a 1-for-1 basis, in shares of the Issuer's common stock. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 21:51 UTC | Envista Holdings Corp NVST · Entity 4007 | Tax withholdingCommon Stock | 2,796 | $38.25 | $106,947.00 |
DisclosureSEC source: 0001757073-23-000013 · wf-form4_167762105466000.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,278 F1 · shares: Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations applicable to the vesting of stock-settled Restricted Stock Units ("RSU"). Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:45 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantPerformance Share Unit · Derivative | 7,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001757073-22-000036 · wf-form4_164617110471562.xml · derivative · entry 4 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,960 Underlying: Common Stock · 7,960 shares Expires not disclosed F5 · derivative.exercise_price: Consists of Performance Share Units ("PSUs") that will vest, if at all, based on certification of achievement of identified performance measures over a three-year performance period. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-200% of the amount reported depending on the level of performance achieved. F5 · derivative.exercise_date: Consists of Performance Share Units ("PSUs") that will vest, if at all, based on certification of achievement of identified performance measures over a three-year performance period. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-200% of the amount reported depending on the level of performance achieved. F5 · derivative.expiration_date: Consists of Performance Share Units ("PSUs") that will vest, if at all, based on certification of achievement of identified performance measures over a three-year performance period. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-200% of the amount reported depending on the level of performance achieved. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:45 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,220 | $0.00 Strike: $48.52 | $0.00 |
DisclosureSEC source: 0001757073-22-000036 · wf-form4_164617110471562.xml · derivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,220 Underlying: Common Stock · 12,220 shares Expires 2032-02-25 F4 · derivative.exercise_date: This Option will vest ratably on each anniversary of the date of grant over three years, subject to continued service through each such date. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:45 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantCommon Stock | 4,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001757073-22-000036 · wf-form4_164617110471562.xml · nonDerivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,074 F3 · shares: Consists of RSUs that will vest ratably on each anniversary of the date of grant over three years, subject to continued service through each such date. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 21:45 UTC | Envista Holdings Corp NVST · Entity 4007 | Tax withholdingCommon Stock | 2,261 | $48.52 | $109,703.72 |
DisclosureSEC source: 0001757073-22-000036 · wf-form4_164617110471562.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,694 F1 · shares: Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations applicable to the vesting of stock-settled Restricted Stock Units ("RSU"). F2 · balance_after: Includes the net balance of RSUs resulting from the vesting of and related tax withholding transaction noted herein. Each RSU will convert on a 1-for-1 basis, in shares of the Issuer's common stock. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 21:10 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantEmployee Stock Option (Right to Buy) · Derivative | 189,900 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0001757073-21-000135 · wf-form4_163536902830598.xml · derivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,900 Underlying: Common Stock · 189,900 shares Expires 2031-10-25 F1 · derivative.exercise_date: This Option will vest ratably on each anniversary of the date of grant over four years, subject to continued service through each such date. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:24 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantEmployee Stock Option (Right to Buy) · Derivative | 42,020 | $0.00 Strike: $37.94 | $0.00 |
DisclosureSEC source: 0001757073-21-000032 · wf-form4_161437462648568.xml · derivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,020 Underlying: Common Stock · 42,020 shares Expires 2031-02-25 F4 · derivative.exercise_date: This Option will vest ratably on each anniversary of the date of grant over three years, subject to continued service through each such date. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:24 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantCommon Stock | 11,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001757073-21-000032 · wf-form4_161437462648568.xml · nonDerivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,955 F3 · shares: Consists of RSUs that will vest ratably on each anniversary of the date of grant over three years, subject to continued service through each such date. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:24 UTC | Envista Holdings Corp NVST · Entity 4007 | Tax withholdingCommon Stock | 990 | $37.94 | $37,560.60 |
DisclosureSEC source: 0001757073-21-000032 · wf-form4_161437462648568.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · shares: Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations applicable to the vesting of stock-settled Restricted Stock Units ("RSU"). F2 · balance_after: Includes the net balance of RSUs resulting from the vesting of and related tax withholding transaction noted herein. Each RSU will convert on a 1-for-1 basis, in shares of the Issuer's common stock. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 01:09 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantEnvista deferred contribution programs - Envista Stock Fund · Derivative | 108 | $35.54 Strike: $0.00 | $3,838.32 |
DisclosureSEC source: 0001757073-21-000020 · wf-form4_161361055409086.xml · derivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108 Underlying: Common Stock · 108 shares Expires not disclosed F1 · derivative.exercise_price: The notional shares convert on a one-for-one basis. F2 · derivative.exercise_date: Company contributions to the Excess Contribution Program ("ECP") consist of matching contributions (based on amounts the reporting person voluntary defers into the Envista Deferred Compensation Plan) and/or non-elective contributions. A participant vests in the matching contribution in the ECP made each year on the first anniversary after it is credited to the participant's account. A participant vests in the non-elective contribution in the ECP made each year on the later of the first anniversary after it is credited to the participant's account, or the date the participant has completed three years of service with Envista. F2 · derivative.expiration_date: Company contributions to the Excess Contribution Program ("ECP") consist of matching contributions (based on amounts the reporting person voluntary defers into the Envista Deferred Compensation Plan) and/or non-elective contributions. A participant vests in the matching contribution in the ECP made each year on the first anniversary after it is credited to the participant's account. A participant vests in the non-elective contribution in the ECP made each year on the later of the first anniversary after it is credited to the participant's account, or the date the participant has completed three years of service with Envista. F3 · derivative.underlying_shares: Represents the Company's annual contribution to the Envista stock fund (the "ECP Stock Fund") in the reporting person's ECP account. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Envista common stock, calculated by dividing the contribution amount by the closing price of Envista common stock as reported on the NYSE as of the first day of the year in which the contribution is made. The price shown in Table II, Column 8 is the closing price per share of Envista common stock as reported on the NYSE on the date the contribution was actually made (or the closing price for the immediately preceding business day, if such date is not a business day). F3 · balance_after: Represents the Company's annual contribution to the Envista stock fund (the "ECP Stock Fund") in the reporting person's ECP account. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Envista common stock, calculated by dividing the contribution amount by the closing price of Envista common stock as reported on the NYSE as of the first day of the year in which the contribution is made. The price shown in Table II, Column 8 is the closing price per share of Envista common stock as reported on the NYSE on the date the contribution was actually made (or the closing price for the immediately preceding business day, if such date is not a business day). F4 · balance_after: Consists of unfunded, notional shares of Envista common stock in the Envista stock fund of the reporting person's ECP account. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 01:42 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantEmployee Stock Option (Right to Buy) · Derivative | 47,020 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0001415889-20-000535 · form4-02262020_050252.xml · derivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,020 Underlying: Common Stock · 47,020 shares Expires 2030-02-25 F2 · derivative.exercise_date: This Option will vest ratably on each anniversary of the date of grant over five years, subject to continued service through each such date. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 01:42 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantCommon Stock | 12,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000535 · form4-02262020_050252.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,740 F1 · shares: Consists of RSUs that will vest ratably on each anniversary of the date of grant over five years, subject to continued service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.